EUCTR2004-000808-40-LT进行中（未招募）不适用
Randomized, open label, multi-center, phase III study onpharmacokinetics, pharmacodynamics, efficacy and safety ofGoserelin 1M Implant HEXAL in patients with advancedprostatic cancer in comparison to Zoladex® 3.6 mg - Gosezol
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Hexal AG
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Histologically confirmed diagnosis of advanced adenocarcinoma of the prostate
- •stage T3-4N0M0, T1-4N1M0 or T1-4N0-1M1,
- •either as newly (within the past 4 weeks) diagnosed adenocarcinoma of the
- •or recurrence of adenocarcinoma of the prostate after previous
- •prostatectomy and/or radiotherapy and/or brachytherapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Patients expected to require additional anti-neoplastic treatment during the study
- •2) Patients at particular risk of developing urethral obstructions and/or spinal cord
- •compression
研究者
相似试验
进行中（未招募）
不适用
Phase III, Multicenter, Open-label, Randomized Study of Erlotinib (Tarceva) Treatment Versus Chemotherapy in Patients with Advanced Non-small-cell Carcinoma of the Lung Who Present Mutations in the Tyrosine Kinase (TK) Domain of Epidermal Growth Factor Receptor (EGFR) - GECP06/01on Small Cells Lung cancerMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2006-003568-73-ITSPANISH LUNG CANCER GROUP146
进行中（未招募）
不适用
Phase III, Multicenter, Open-label, Randomized Study of Erlotinib (Tarceva®) Treatment Versus Chemotherapy in Patients with Advanced Non-small-cell Carcinoma of the Lung Who Present Mutations in the Tyrosine Kinase (TK) Domain of Epidermal Growth Factor Receptor (EGFR)on-squamous-cell, non-small-cell lung cancer in stage IIIB and IVMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2006-003568-73-FRGrupo Espagnol de Cancer de Pulmon146
进行中（未招募）
3 期
Clinical trial/study for lung cancer patients with ROS1 positiveCTRI/2022/04/041861F HoffmannLa Roche Ltd
进行中（未招募）
1 期
Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma.Relapsed/Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2009-016138-29-IEPharma Mar, S.A.250
进行中（未招募）
1 期
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma - ADMYRE: Aplidin - Dexamethasone in RElapsed/Refractory MYelomaRelapsed/refractory multiple myelomaMedDRA version: 12.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2009-016138-29-ITPHARMA MAR255